Differential absolute plasma IL-6 concentrations between two immunoassay platforms in intensive care unit patients with COVID-19

OBJECTIVES: Explore whether plasma IL-6 levels are similar across biomarker platforms and association with COVID-19 clinical outcomes. METHODS: Plasma IL-6 concentrations were measured on 191 COVID-19 patients using the Roche Elecsys IL-6 assay and the Meso Scale Discovery assay. RESULTS: Correlatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Bhatraju, Pavan K, Morrell, Eric D, O'Connor, Nicholas G, Choi, Audrey, Fitzpatrick, Michael, Smith, Craig H, Wurfel, Mark M, Liles, Wayne Conrad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Future Medicine Ltd 2023
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10652295/
https://www.ncbi.nlm.nih.gov/pubmed/37650680
http://dx.doi.org/10.2217/bmm-2023-0073
Descripción
Sumario:OBJECTIVES: Explore whether plasma IL-6 levels are similar across biomarker platforms and association with COVID-19 clinical outcomes. METHODS: Plasma IL-6 concentrations were measured on 191 COVID-19 patients using the Roche Elecsys IL-6 assay and the Meso Scale Discovery assay. RESULTS: Correlation of IL-6 levels between platforms was high (r = 0.87; 95% CI: 0.82–0.89); however, agreement was low (bias: 147.2 pg/ml; 95% limits of agreement: -489.5–783.9 pg/ml). The optimal IL-6 threshold to predict invasive mechanical ventilation and in-hospital mortality were 3- and 3.4-fold higher in Roche compared with Meso Scale Discovery, respectively. CONCLUSION: The absolute IL-6 threshold to predict outcomes was consistently higher using the Roche platform, and IL-6 thresholds to inform prognosis vary based on the biomarker platform.

Ejemplares similares